These results could be explained using the enhanced levels of anti-pneumococcal antibodies and IFN-γ, both in the respiratory tract and blood, which would account for the more efficient control of S. pneumoniae secondary infection and for the remarkable effectiveness of BLPs. The gene discussed is IFNG; the disease is infection.